Clinical trials: Total Neoadjuvant Therapy
Rectum Cancer, Adenocarcinoma
ADAR1 Expression Level in Rectal Cancer
Total neoadjuvant therapy (TNT) is currently the standard treatment for locally/locally advanced rectal cancer due to better response and fewer distant metastases.
- Trial name
- ADAR1TNT (NCT07108348)
- Testing
- Adenosine deaminase acting on RNA1
- Where
- Turkey (Türkiye)
- Volunteers
- 50 people
- Sponsor
- Necmettin Erbakan University
Locally Advanced Rectal Cancer
A Single-arm Phase II Clinical Study of Camrelizumab Combined With Long-course Chemoradiotherapy for Total Neoadjuvant Therapy in Locally Advanced Low pMMR/MSS Rectal Cancer
In pMMR/MSS locally advanced rectal cancer, can the innovative "chemo-immunotherapy induction + LCRT + chemo-immunotherapy consolidation" approach significantly improve the complete response rate and create opportunities for…
- Trial name
- NCT07527026
- Testing
- Camrelizumab
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Chinese PLA General Hospital
Locally Advanced Rectal Cancer
TNT of SCRT+CAPOX vs SCRT+CAPOXIRI for Locally Advanced Rectal Cancer
This trial is a multicenter randomized Phase III study to verify the superiority of short-course preoperative radiation (SCRT) and CAPOXIRI over SCRT and CAPOX as preoperative treatments for locally advanced rectal cancer.
- Trial name
- ENSEMBLE (NCT05646511)
- Testing
- SCRT, CAPOX, CAPOXIRI
- Where
- 34 sites in Japan
- Volunteers
- 608 people
- Sponsor
- National Cancer Center Hospital East
Esophagogastric Adenocarcinoma
TNT With FLOT/Durvalumab Plus Post-OP Durvalumab for Resectable Gastroesophageal Adenocarcinoma
This trial is designed to evaluate a total neoadjuvant approach using D-FLOT as the new standard backbone in patients with resectable esophagogastric adenocarcinoma.
- Trial name
- NCT07507968
- Testing
- Durvalumab
- Where
- 29 sites in Germany, Spain
- Volunteers
- 101 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Rectal Cancer
Total Neoadjuvant Treatment of Rectal Cancer by MRI-guided Radiotherapy
The TNTRect trial is a prospective observational study that will evaluate the outcome of MR-guided stereotactic body radiotherapy (SBRT) with a simultaneous integrated boost in a hypofractionated treatment of rectum cancer.
- Trial name
- TNTRect (NCT05916040)
- Testing
- Radiotherapy with MRIdian with simultaneous integrated boost, Questionnaires before, during and after radiotherapy
- Where
- Belgium
- Volunteers
- 35 people
- Sponsor
- Universitair Ziekenhuis Brussel
Rectal Cancer
Total Neoadjuvant Therapy Versus Standard Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer
The National Comprehensive Cancer Network (NCCN) guidelines recommend trimodality treatment for patients with middle and low LARC with neoadjuvant chemoradiotherapy (NA-CRT), surgical resection with TME, plus additional…
- Trial name
- NCT05274945
- Testing
- Radiotherapy, consolidation chemotherapy, TME or APR
- Where
- Egypt
- Volunteers
- 58 people
- Sponsor
- Alexandria University
Rectal Cancer, Rectal Adenocarcinoma
SCRT Followed by CAPOX + Bev ± PD-1 Inhibitor for TNT in LARC
This study aims to evaluate the efficacy and safety of short-course radiotherapy combined with CAPOX plus bevacizumab with or without a PD-1 inhibitor in patients with locally advanced rectal cancer (LARC).
- Conditions
- Rectal Cancer, Rectal Adenocarcinoma, Rectal Cancer, Radiotherapy, Rectal Cancer Patients
- Trial name
- NCT07198165
- Testing
- PD-1 inhibitor based immunotherapy
- Where
- China
- Volunteers
- 104 people
- Sponsor
- Ruijin Hospital
Rectal Cancer, Surgery
Local Excision Versus Total Mesorectal Excision In Pathological Complete Response (ypT0-1cN0) Mid- Or Low-Rectal Cancer After Neoadjuvant Therapy
Patients with cT2-4aN0-2M0 mid- or low-rectal cancer received neoadjuvant chemotherapy or combined chemoradiotherapy. Good responders (cT0-1N0) patients received local excision 4-8 weeks after treatment.
- Trial name
- NCT03548844
- Testing
- local excision, total mesorectal excision
- Where
- China
- Volunteers
- 326 people
- Sponsor
- Yanhong Deng
Rectal Cancer
Total Neoadjuvant Treatment ±Immunotherapy for High Risk Locally Advanced Rectal Cancer (TNTi)
The goal of this clinical trial is to compare the PCR rate between Total Neoadjuvant Treatment ±Immunotherapy in high risk locally advanced rectal cancer.
- Trial name
- NCT06229041
- Testing
- Camrelizumab ＋Immunotherapy
- Where
- China
- Volunteers
- 472 people
- Sponsor
- Peking University Cancer Hospital & Institute
Rectal Cancer
A Study of Total Neoadjuvant Therapy for High-risk Locally Advanced Rectal Cancer
A Phase II Study of Total Neoadjuvant Therapy for High-risk Locally Advanced Rectal Cancer
- Trial name
- NCT04543695
- Testing
- Concurrent Chemoradiotherapy, XELOX, mFOLFOX
- Where
- China
- Volunteers
- 255 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Locally Advanced Rectal Carcinoma, Neoadjuvant Treatment
Longitudinal Multimodal Response Assessment During Neoadjuvant Treatment of Rectal Cancer
This pilot study aims to trial multimodal early response assessment to enable therapy adaptions in the context of non-operative therapy strategies of locally advanced rectal cancer (LARC) for development of a non-invasive…
- Conditions
- Locally Advanced Rectal Carcinoma, Neoadjuvant Treatment, Radiotherapy, Adaptive Treatment
- Trial name
- PRIMO (NCT05524012)
- Testing
- Blood sample, MRI scan
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Jena University Hospital
Locally Advanced Rectal Cancer
Irinotecan Liposomes in Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer
This study enrolled patients with locally advanced rectal cancer. The experimental group received irinotecan liposomes combined with standard total neoadjuvant therapy (TNT), while the control group received standard TNT.
- Trial name
- CinClare-2 (NCT07074353)
- Testing
- NALIRI, LCRT, FOLFOX
- Where
- China
- Volunteers
- 360 people
- Sponsor
- Zhejiang Cancer Hospital
Locally Advanced Rectal Cancer, Total Neoadjuvant Treatment
Total Neoadjuvant Chemoradiotherapy Plus Anti-PD-1 in Subperitoneal Patients With Locally Advanced Rectal CancerPatients With Locally Advanced Rectal Cancer: A Prospective, Single Arm, Exploratory Study
Previously, preliminary results, from a subgroup analysis of STARS-RC03 (NCT04906044) conducted by our research team, showed that the 6-cycles consolidation chemotherapy combining with anti-PD-1 therapy had a better tumor…
- Conditions
- Locally Advanced Rectal Cancer, Total Neoadjuvant Treatment, Anti-PD-1
- Trial name
- NCT05998122
- Testing
- nCRT → (CapeOX+Sintilimab)×6 → Surgery/W&W
- Where
- China
- Volunteers
- 45 people
- Sponsor
- The First Hospital of Jilin University
Locally Advanced Rectal Cancer
Short-course Radiotherapy Followed by Consolidation Chemotherapy. 2021-001206-29
The aim of the ShorTrip trail is to evaluate the activity and the safety of total neoadjuvant strategy with FOLFOXIRI as consolidation therapy preceded by short-course radiotherapy and followed by surgery in LARC patients.
- Trial name
- ShorTrip (NCT05253846)
- Testing
- Irinotecan, Oxaliplatin, Lederfolin
- Where
- Italy
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Gruppo Oncologico del Nord-Ovest